AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06323044 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Medical Device Usage and Evaluation
Description: Use MEMS device
Study NCT06323044 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Ancillary studies
Study NCT06323044 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Survey Administration
Description: Ancillary studies
Study NCT05204550 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: unfractionated heparin
Description: intranasal
Study NCT05204550 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9%sodium chloride
Description: intranasal
Study NCT06680934 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Molecular genetic testing and audiometry
Description: Genetic testing and audiometry are the interventions of interest
Study NCT06674382 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Haploidentical hematopoietic stem cell transplantation
Description: This is a single-arm study in which all patients will undergo haploidentical hematopoietic stem cell transplantation for the treatment of myelofibrosis.~Pre-transplant Evaluation:~Evaluation includes status of primary Disease, donor specific antibodies (DSA), organ function (assessments for heart, liver, lungs, kidneys, and the nervous system), and Spleen size.~Transplantation Protocol:~Conditioning Regimen:~Dac/TT/Bu/Flu/ATG regimen:~Decitabine 100 mg/m², on day -12. Thiotepa (TT) 5 mg/kg/day, on days -11 and -10. Busulfan 0.8 mg/kg body weight, every 6 hours, on days -8 to -6. Fludarabine 30 mg/m², once daily, on days -6 to -2. Anti-thymocyte globulin (ATG) 2.5 mg/kg body weight, once daily, on days -5 to -2.~Transplant Donor: Haploidentical donor. GVHD (Graft-versus-Host Disease) Prophylaxis Regimen: Cyclosporine, mycophenolate mofetil, and short-course methotrexate for GVHD prevention.~Graft:~Target MNC (Mononuclear Cells): 6-8 × 10⁸/kg. Target CD34+ stem cells: 5 × 10⁶/kg
Study NCT06674109 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin 10 mg
Description: For the empagliflozin arm, participants will take 10 mg daily.
Study NCT06674109 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants in the placebo arm will take a placebo daily.
Study NCT05502341 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bictegravir
Description: Tablets administered orally without regard to food
Study NCT05502341 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenacapavir
Description: Tablets administered orally without regard to food
Study NCT05502341 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIC/LEN FDC
Description: Tablets administered orally without regard to food
Study NCT05502341 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Stable Baseline Regimen
Description: SBR will include a combination of antiretroviral (ARV) regimen. ARV regimen may include the following, except for participants taking a single tablet regimen or taking a complete parenteral regimen (Cabenuva).~* Nucleos(t)ide Reverse Transcriptase Inhibitors:~  * Abacavir~ * Emtricitabine~ * Lamivudine~ * Tenofovir alafenamide~ * Tenofovir disoproxil fumarate~ * Zidovudine~* Non-Nucleosite Reverse Transcriptase Inhibitors:~  * Delavirdine~ * Efavirenz~ * Nevirapine~ * Rilpivirine~ * Doravirine~* Integrase Inhibitors:~  * Bictegravir~ * Cabotegravir~ * Dolutegravir~ * Elvitegravir~ * Raltegravir~* Protease Inhibitors:~  * Atazanavir~ * Darunavir~ * Fosamprenavir~ * Indinavir~ * Lopinavir~ * Nelfinavir~ * Saquinavir~ * Tipranavir~* Chemokine Co-receptor 5 (CCR5) Antagonist:~  * Maraviroc~* Fusion Inhibitors:~  * Enfuvirtide~* gp120 Attachment Inhibitor:~  * Fostemsavir~* Anti-CD4 Monoclonal Antibodies:~  * Ibalizumab-uiyk
Study NCT05957367 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DCC-3116
Description: Oral Tablet Formulation
Study NCT05957367 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ripretinib
Description: Oral Tablet Formulation
Study NCT06229457 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Girls PLAY program
Description: Girls PLAY program (8-12 weeks) will include 1) a series of in-person sessions, led by Boys and Girls Clubs staff at the Boys and Girls Club sites, and 2) take-home activities. In-person sessions (60-75 min; 2-3x/week) will center around a different developmentally appropriate sport each week. Lesson plans will outline games/activities in which youth engage in fundamental, sport-specific movement skills. Lesson plans will be delivered by Boys and Girls Club leaders using acts of instruction derived from Self-Determination Theory. Take home activities will 1) summarize and add on to the week's in-person sessions and 2) be adapted for delivery by parents and/or self-guided participation by youth. Take-home activities will provide information for engaging in the past week's activities as well as additional activities that parents and youth can participate in together.
Study NCT06543394 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Primer postcard
Description: Mailed primer postcard
Study NCT06543394 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control recruitment letter
Description: Mailed recruitment letter with usual care message framing
Study NCT06543394 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Behavioral theory-informed recruitment letter
Description: Mailed recruitment letter with prospect-theory informed message framing
Study NCT06543394 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: 2 phone calls
Description: Up to 2 phone call attempts to schedule patient for a clinical pharmacist adherence counseling visit
Study NCT06543394 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: 4 phone calls
Description: Up to 4 phone call attempts to schedule patient for a clinical pharmacist adherence counseling visit
Study NCT06337500 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neurophysiological measure (EEG)
Description: Cerebral electric activity recorded with EEG
Study NCT06337500 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Neurophysiological measure (EEG)
Description: Cerebral electric activity recorded with EEG
Study NCT06337500 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey
Description: Participants complete a survey to evaluate their exposure to screens and their assessment of the laboratory task performed
Study NCT06337500 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Survey
Description: Participants complete a survey to evaluate their exposure to screens and their assessment of the laboratory task performed
Study NCT05887648 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SinDance
Description: One face-to-face briefing session (20 min) will be offered to participants in the SinDance group as part of promoting physical activity and safe exercise for older adults.~Participants will be asked to engage in SinDance 3 times a week for 6 weeks. Each session will last for about 30-40 mins, including 5 mins warm up exercise before the game and 5 mins cool down exercise afterwards.~All the game play sessions will be conducted in LB centres. Each participant will play the game individually.~To play the game, participants will dance to the dance moves shown on the screen (on the external monitor or the projected screen) and as they get each move right, they will be awarded points. The more accurate their moves are, the more points they get in the game.~During the gameplay, the participants will be instructed to stop and rest if they are tired. A RN/RA will be on site to observe the safety of exergaming and to help resolve technical issues as they arise.
Study NCT06199037 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1707
Description: 1 cohort of Mild Cognitive Impairment Due to Alzheimer's Disease or Mild Alzheimer's Disease patients will receive SHR-1707 injection
Study NCT06199037 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: SHR-1707 placebo
Description: 1 cohort of Mild Cognitive Impairment Due to Alzheimer's Disease or Mild Alzheimer's Disease patients will receive SHR-1707 placebo injection
Study NCT05651659 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TIME model in the prevention and treatment of crises in frail community-dwelling people
Description: TIME is a manual-based, multicomponent programme that will include a rigorous assessment of the crises, one or more interdisciplinary case conferences and the testing and evaluation of customised treatment measures.This multicomponent interdisciplinary model consisting of three overlapping phases. First the assessment phase where the care staff and the physician collaborate in a comprehensive bio-psychosocial assessment. The second phase is the reflection phase with interdisciplinary case conferences based on principles from cognitive behavioural therapy and abc-method, where a customized treatment plan is developed. The abc-method from cognitive behavioural therapy is used as an analytic tool for the analyses of the complex challenges in the case conferences. In the third phase the treatment plan is implemented and evaluated systematically.
Study NCT05591742 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: FEMIDUR®
Description: Femidur® consist of 2 vaginal lactobacillis; Lactobacillus rhamnosus GR-1® and Lactobacillus reuteri RC-14®. One tablet a day.~Placebo Z Cap V-3 Pla; mainly maltodextrin
Study NCT05591742 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Z Cap V-3 Pla
Description: Consist mainly of maltodextrin. One tablet a day.
Study NCT06697470 — intervention group
Intervention type: DEVICE
Intervention: Ultrasound and Bioelectrical Impedance Analysis for Muscle Thickness and Fluid Balance Assessment Translation
Description: This intervention involves the use of ultrasound and bioelectrical impedance analysis (BIA) to monitor changes in muscle thickness and assess fluid balance in critically ill patients. Measurements will be taken daily during the patients' ICU stay, with a focus on rectus femoris, tibialis anterior, and biceps brachii muscles, as well as total body fluid compartments. The study aims to explore correlations between muscle thickness variations, fluid balance, and patient outcomes.
Study NCT06697015 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pendulum Exercises
Description: In this group, 18 participants will perform pendulum exercises, which involve leaning forward and allowing the affected arm to hang down, swinging it gently in small circular or side-to-side motions. This exercise is designed to enhance shoulder mobility and promote relaxation of the rotator cuff muscles without straining the shoulder joint. The pendulum movement helps improve circulation and relieve tension in the shoulder area, making it a suitable intervention for individuals experiencing rotator cuff pain.
Study NCT06697015 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Serratus Punch Exercises
Description: In this group, 18 participants will engage in serratus punch exercises, focusing on strengthening the serratus anterior muscle. Participants will perform a punching motion by extending the arm forward while maintaining shoulder stability. This exercise activates the shoulder muscles to enhance scapular control, supporting the rotator cuff and improving overall shoulder function. The goal is to build strength in the stabilizing muscles, which can help alleviate pain and enhance mobility in participants suffering from rotator cuff issues.
Study NCT06697873 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental Group: A
Description: 21 participants will receive both Rhythmical stabilization and closed chain kinetic exercise followed by a warm up session with stretching 5 minutes and cool down session with 5 minutes
Study NCT06697873 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental: Group B
Description: 21 participants will receive Rhythmical stabilization training program followed by a warm up session with stretching 5 minutes and cool down session with 5 minutes.
Study NCT06697574 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hypnosis aimed at stress reduction and health of the oral mucosa
Description: * Induction.~* Hypnotic relaxation and escalating deepening of hypnotic trance.~* Suggestions for healing and wellness of the oral mucosa and for balanced and optimal performance of the immune system, tailoring metaphors and images based on interview with patients.~...the interior of the mouth is soft, healthy pink, intact and whole. It functions optimally as it should - enabling joyful eating and tasting, speaking with ease for any needed expression, any function of the mouth that needs to be used can be done so easily.~The immune system is very wise - it knows perfectly how to function in a balanced and harmonious way. Its wisdom enables it to act if the body needs defense and to standby and rest if it does not.~* Ego strengthening.~* Anchoring - using a predetermined mark selected by the patient.~* Dehypnotisation.
Study NCT06697574 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psychoeducation
Description: A short explanation about the psycho-neuro-immune system and its part in oral lichen planus
Study NCT06697574 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychoeducation
Description: A short explanation about the psycho-neuro-immune system and its part in oral lichen planus
Study NCT06696560 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Minimal Invasive Approaches in Aortic surgeries.
Description: Minimal Invasive Approaches For Aortic Valvular and Subvalvular Surgeries
Study NCT06711978 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mirogabalin
Description: Participants will receive Mirogabalin at a dose of twice daily for 4 weeks to manage CIPN pain.
Study NCT06711978 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duloxetine
Description: Participants will receive Duloxetine at a dose of once daily for 4 weeks to manage CIPN pain.
Study NCT06712277 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Video training
Description: After the procedure, caregivers will be trained on tube care and patient feeding by demonstrating and performing the procedure on an iPad.
Study NCT05562830 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Zilovertamab vedotin
Description: Administered via intravenous (IV) infusion on day 1 and day 8 of Q3W cycles
Study NCT04308551 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indobufen
Description: Indobufen Tablets
Study NCT04308551 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Description: Aspirin Tablets
Study NCT06378762 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Endurance Exercise
Description: 30 minutes of running at an intensity corresponding to the heavy-domain (between the first and second ventilatory thresholds)
Study NCT06378762 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Strength Exercise
Description: Combination of strength and power exercises Weeks 1-5 focus on building maximal strength Weeks 6-11 focus on maintaining maximal strength and improve muscle power
Study NCT06378762 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Concurrent Exercise
Description: Combining both strength and endurance training programs, with strength preceding endurance, incorporating a 20-min rest period between each modality
Study NCT05696730 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Communication intervention about sexuality in people with COPD
Description: COSY is a communication intervention which consists of one face to face counselling (75 min) and two 30-min telephone call counselling.~Patients assigned to the intervention group will get the COSY communication intervention with a special focus on the positive impact of sexuality on wellbeing plus specific motivation for physical activity. Together with the patient, a personalized re-enforcement instrument, the COSY-Compass, is elaborated to set individual goals and motivation for physical activity over the whole intervention period (3 months).~Participants will learn to understand the positive effect of regular physical activity on physical, mental, and cognitive wellbeing and a more fulfilling sex life as well as get inspiration about the spectrum and possible expressions and manifestations of caring and intimacy with oneself.
Study NCT05359900 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pain neuroscience education
Description: Pain neuroscience education lecture
Study NCT05359900 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Red Flag Education
Description: Red Flag education lecture
Study NCT05339906 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ZOV.ai digital therapy candidate
Description: ZOV.ai is a novel auditory neuro modulating technology that leverages euphonic music tracks with broad-spectrum binaural beats to induce selective EEG spectral power changes to improve stuttering symptoms
Study NCT06166082 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active iTBS-DLPFC
Description: Participants will receive 10 sessions per day of 1800 pulses per session, lasting for 5 days.
Study NCT06462976 — intervention group
Intervention type: OTHER
Intervention: mechanical power calculation
Description: Mechanical Power= 0.098×Minute ventilation× (peak pressure - 0.5 (plato pressure-PEEP)). These parameters are monitored on the monitor while the patient is mechanically ventilated and placed into the equation
Study NCT05469958 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hypothermia prevention bundle
Description: pre-warming of the patient for 10 minutes with forced air blankets before the surgery starts, which will be maintained during surgery and during the immediate postoperative period, the intravenous perfusions will be warmed up to 38 Celsius degree (ºC) and the environmental temperature will be controlled at 21 Celsius degree (ºC) during surgery
Study NCT05469958 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional care
Description: the patient will be attended with textile blankets on patient demand
Study NCT04370444 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Phallus Length Reducer
Description: Phallus Length Reducer
Study NCT04370444 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Self-assessment of dyspareunia
Description: Use of a vaginal insert to self assess dyspareunia
Study NCT04370444 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Self-assessment of dyspareunia
Description: Use of a vaginal insert to self assess dyspareunia
Study NCT06166082 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham iTBS-DLPFC
Description: The parameters in the sham arms are the same as the active stimulation groups. Stimulation was delivered by the same device as the active group fitted with a sham coil.
Study NCT06250426 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Pre-thickened oral nutritional supplement with a cooling sensation flavour
Description: Pre-thickened oral nutritional supplement (ONS) drink with cooling sensation flavour
Study NCT06692491 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyrotinib
Description: Pyrotinib 400mg, qd Patients with advanced rare tumours who failed to standard treatment carrying HER-2 mutation or HER-2 over expression/amplification will be administrated with Pyrotinib under the guidance of MTB.
Study NCT04444349 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Coenzyme Q10
Description: Coenzyme Q10 is a cardiovascular health supplement. It is a component of the electron transport chain and participates in aerobic cellular respiration, which generates energy in the form of ATP. The ingredients in Coenzyme Q10 help regulate the body's production of free radicals, strengthen the arteries and heart, and reverse oxidation.
Study NCT04444349 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: SHAM_COMPARATOR
Intervention: Standard Medical Therapy
Description: Patients only received standard medical therapy without CoQ10.
Study NCT06692491 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib
Description: Imatinib 400mg, qd Patients with advanced rare tumours who failed to standard treatment carrying CKIT mutation will be administrated with imatinib under the guidance of MTB.
Study NCT03978117 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Freeze dried Powder
Description: Freeze dried powder containing gluconasturtiin, which when added to a provided juice, will result in a target dose of up to 40 mg/day of 2-phenethyl isothiocyanate (PEITC). Preparation consumed at breakfast, lunch and dinner 3x daily for 2 weeks.
Study NCT03978117 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Freeze dried Powder
Description: Freeze dried powder containing gluconasturtiin, which when added to a provided juice, will result in a target dose of up to 40 mg/day of 2-phenethyl isothiocyanate (PEITC). Preparation consumed at breakfast, lunch and dinner 3x daily for 2 weeks.
Study NCT03978117 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo Preparation
Description: Placebo powder added to a provided juice. Preparation consumed at breakfast, lunch and dinner 3x daily for 2 weeks.
Study NCT03978117 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Preparation
Description: Placebo powder added to a provided juice. Preparation consumed at breakfast, lunch and dinner 3x daily for 2 weeks.
Study NCT06692491 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: Palbociclib 125mg, 21/7 dosing schedule Patients with advanced rare tumours who failed to standard treatment following HR(+)/HER-2(-) will be administrated with palbociclib under the guidance of MTB.